Biotechnological sovereignty is not a mere nationalist concept, it is a necessity for Colombia and Latin America.

During the pandemic, Latin American countries suffered the collapse of their health systems. This was caused by the high demand for care of patients infected with SARS-CoV-2, which was added to the care of patients with other diseases. The significant increase in demand for health services caused medical and laboratory supplies to decline rapidly. The COVID-19 pandemic exacerbated a health crisis in several developing countries, mainly caused by insufficient systematic policies for integrating scientific knowledge. The current Colombian government must formulate a Biotechnological or Biosecurity Sovereignty Law that guarantees scientific autonomy, ensuring that Colombia is self-sufficient in Science, Technology, and Innovation. Colombian government should also focus on establishing and developing pharmaceutical chemical production by acquiring active chemical ingredients from other countries. This strategy could reduce the production costs and final prices of medicines, as well as generate high-level employment and wealth for the country. In this way, the Colombian government could prevent shortage of essential medicines and excessive price increases by commercial intermediation. In conclusion, the manuscript focuses on the lack of biotechnological sovereignty in Colombia. We propose a model of a Latin American Science and Technology ecosystem to achieve biotechnological sovereignty via state funding of research, strengthening universities, and fostering participation among private companies and Ministries of Science, Education, Trade, and Health. Scientific autonomy based on innovative processes that strengthen biotechnological independence can contribute to the economy by generating gross added value, creating high-quality employment, and facilitating the appropriation and social dissemination of knowledge, and cost reduction.

Biotechnological sovereignty is not a mere nationalist concept, it is a necessity for Colombia and Latin America / Soberanía biotecnológica no es un mero concepto nacionalista, pero una necesidad para Colombia y América Latina / A soberania biotecnológica não é um mero conceito nacionalista, é uma necessidade para a Colômbia e a América Latina

Abstract: During the pandemic, Latin American countries suffered the collapse of their health systems. This was caused by the high demand for care of patients infected with SARS-CoV-2, which was added to the care of patients with other diseases. The significant increase in demand for health services caused medical and laboratory supplies to decline rapidly. The COVID-19 pandemic exacerbated a health crisis in several developing countries, mainly caused by insufficient systematic policies for integrating scientific knowledge. The current Colombian government must formulate a Biotechnological or Biosecurity Sovereignty Law that guarantees scientific autonomy, ensuring that Colombia is self-sufficient in Science, Technology, and Innovation. Colombian government should also focus on establishing and developing pharmaceutical chemical production by acquiring active chemical ingredients from other countries. This strategy could reduce the production costs and final prices of medicines, as well as generate high-level employment and wealth for the country. In this way, the Colombian government could prevent shortage of essential medicines and excessive price increases by commercial intermediation. In conclusion, the manuscript focuses on the lack of biotechnological sovereignty in Colombia. We propose a model of a Latin American Science and Technology ecosystem to achieve biotechnological sovereignty via state funding of research, strengthening universities, and fostering participation among private companies and Ministries of Science, Education, Trade, and Health. Scientific autonomy based on innovative processes that strengthen biotechnological independence can contribute to the economy by generating gross added value, creating high-quality employment, and facilitating the appropriation and social dissemination of knowledge, and cost reduction.

Resumen: Durante la pandemia, los países latinoamericanos vieron colapsar sus sistemas de salud. Esto se debió a la alta demanda de atención para las personas contagiadas con SARS-CoV-2 y a la atención de pacientes con otros tipos de enfermedades. El aumento significativo de la demanda de los servicios de salud llevó a la rápida disminución de los suministros médicos y de laboratorio. La pandemia de la COVID-19 intensificó la crisis sanitaria en los países en desarrollo, principalmente por una política sistemática e insuficiente de apropiación del conocimiento científico. Si el actual gobierno colombiano formulara una Ley de Soberanía Biotecnológica o de Bioseguridad por la cual se garantizaría la autonomía científica, esto conduciría a una autonomía de Colombia en Ciencia, Tecnología e Innovación. El Gobierno de Colombia también debería centrarse en fomentar y desarrollar la producción de productos químicos farmacéuticos mediante el abastecimiento de ingredientes químicos activos de otros países. Esta estrategia favorece la reducción de costos de producción y del precio final de los medicamentos, además de generar empleos de alto nivel y riqueza para el país. De esta manera, no habría escasez de medicamentos esenciales, ni alzas excesivas de precios en la intermediación comercial. Pero, la realidad es que hay una débil soberanía biotecnológica en Colombia. En este texto se propone un modelo de ecosistema basado en Ciencia y Tecnología para que Latinoamérica logre la soberanía biotecnológica mediante el financiamiento estatal a la investigación en universidades, con la participación de entidades privadas y Ministerios de Ciencia, Educación, Comercio y Salud. La autonomía científica se basa en procesos de innovación que implican el fortalecimiento de la autonomía biotecnológica.

Resumo: Durante a pandemia, os países latino-americanos sofreram o colapso de seus sistemas de saúde. Isso foi causado pela alta demanda de atendimento aos infectados pelo SARS-CoV-2, que somou-se, em paralelo, ao atendimento de pacientes com outros tipos de doenças. O aumento significativo na demanda por serviços de saúde levou à rápida diminuição dos suprimentos médicos e laboratoriais. A pandemia de COVID-19 acelerou, nos países em desenvolvimento, uma crise sanitária causada principalmente por uma política sistemática e insuficiente de apropriação do conhecimento científico. O atual governo colombiano deve formular uma Lei de Soberania Biotecnológica ou de Biossegurança que garanta a autonomia científica, o que leva à autonomia que garante que a Colômbia seja autossuficiente em Ciência, Tecnologia e Inovação. O governo da Colômbia também deve se concentrar em estabelecer e desenvolver a produção de produtos químicos farmacêuticos, adquirindo ingredientes químicos ativos de outros países. Essa estratégia reduz os custos de produção e o preço final dos medicamentos, além de gerar empregos de alto nível e riqueza para o país. Desta forma, não haveria escassez de medicamentos essenciais, nem estaríamos sujeitos a aumentos excessivos de preços por intermediação comercial. Em conclusão, o manuscrito foca na fracassada soberania biotecnológica na Colômbia. Propomos um modelo de ecossistema latino-americano de Ciência e Tecnologia para alcançar a soberania biotecnológica por meio do financiamento estatal do fortalecimento da pesquisa das universidades, com a participação de empresas privadas e Ministérios da Ciência, Educação, Comércio e Saúde. A autonomia científica é baseada em processos de inovação que fortalecem a autonomia biotecnológica.

Safety of voluntary interruption of pregnancy (VIP) in two healthcare institutions in Medellín, Colombia, in 2019. Historical cohort / Seguridad de la Interrupción Voluntaria del Embarazo (IVE) en dos Instituciones Prestadoras de Salud en Medellín, Colombia, en 2019. Cohorte histórica.

Objectives: To characterize a cohort of women with voluntary interruption of pregnancy (VIP) and to describe intraoperative complications according to the technique used. Materials and Methods: Descriptive study in a historical cohort of women undergoing VIP in two healthcare institutions in Medellín, Colombia, in 2019. Women with pelvic infection and STIs were excluded. Consecutive sampling was used. Sociodemographic, sexual and reproductive health, clinical characteristics of the pregnancy, legal cause of the VIP, characteristics of the care process and complications of the VIP techniques up to post-procedural day 7 were the measured variables. A descriptive analysis was carried out. Results: Overall, 1,520 women were identified as eligible during the study period. Of them, 46 were intervened in other institutions, leaving 1,474 candidates to enter the study. Of them, 30 were excluded because of pelvic or sexually transmitted infections. Ultimately, 1,444 pregnant women were included in the analysis. Risk to the mother's health was the most frequent legal cause in 94.3% of cases. Ninety-nine percent of women received pre-procedural counseling, and 78.4% agreed to use some form of contraception after VIP. Manual vacuum aspiration (MVA) was used in 95.6% of women and dilation and curettage (D&C) in 4.4%. Complications up to postoperative day 7 occurred in 17.56%, and there were no complications in the MVA group; 80% of women attended the follow-up visit on post-VIP day 7. Conclusions: MVA is a safe procedure which was not associated with complications within the first seven post-VIP days in the studied patients. Prospective studies to assess the safety and cost of the different VIP options are required.

Objetivos: caracterizar una cohorte de mujeres con interrupción voluntaria del embarazo (IVE) y describir las complicaciones intraoperatorias según la técnica aplicada. Materiales y métodos: estudio descriptivo, de cohorte histórica en mujeres intervenidas a IVE en dos Instituciones Prestadoras de Salud-IPS en Medellín, Colombia, en el 2019. Se excluyeron aquellas mujeres con infección pélvica, e ITS. Se realizó un muestreo consecutivo, se evaluaron variables sociodemográficas, de salud sexual y reproductiva, características clínicas del embarazo, causa legal de la IVE, características de la atención y las complicaciones hasta los 7 días posteriores al procedimiento de las técnicas de IVE. Finalmente, se hace análisis descriptivo. Resultados: durante el periodo de estudio hubo 1.520 mujeres elegibles de las cuales 46 fueron intervenidas en otras instituciones por lo que quedaron 1.474 candidatas a ingresar al estudio, de estas se excluyeron 30 por presentar infecciones pélvicas o de transmisión sexual, por lo que, finalmente, se analizaron 1.444 mujeres gestantes. Los riesgos para la salud de la mujer fueron la causa legal más frecuente con un 94,3%. El 99% de las mujeres tenían asesoría previa, y el 78,4% aceptó algún método anticonceptivo post-IVE. El 95,6% de las mujeres fueron intervenidas por la técnica de aspiración manual endouterina (AMEU) y al 4,4% se la practicó la técnica de dilatación y curetaje (D&C). En un 17,56% de las pacientes intervenidas con D&C se presentaron complicaciones hasta el séptimo día posoperatorio, no hubo complicaciones en el grupo sometido a AMEU, el 80% de las mujeres asistieron a control el séptimo día post-IVE. Conclusiones: la AMEU es un procedimiento seguro que no generó complicaciones intraoperatorias en el procedimiento hasta los primeros siete días después de la IVE, en las pacientes estudiadas. Se requieren estudios prospectivos que evalúen la seguridad y costos de las diferentes alternativas de IVE.

Seguridad de la Interrupción Voluntaria del Embarazo (IVE) en dos Instituciones Prestadoras de Salud en Medellín, Colombia, en 2019. Cohorte histórica / Safety of voluntary interruption of pregnancy (VIP) in two healthcare institutions in Medellín, Colombia, in 2019. Historical cohort

RESUMEN Objetivos: caracterizar una cohorte de mujeres con interrupción voluntaria del embarazo (IVE) y describir las complicaciones intraoperatorias según la técnica aplicada. Materiales y métodos: estudio descriptivo, de cohorte histórica en mujeres intervenidas a IVE en dos Instituciones Prestadoras de Salud-IPS en Medellín, Colombia, en el 2019. Se excluyeron aquellas mujeres con infección pélvica, e infecciones de transmisión sexual (ITS). Se realizó un muestreo consecutivo, se evaluaron variables sociodemográficas, de salud sexual y reproductiva, características clínicas del embarazo, causa legal de la IVE, características de la atención y las complicaciones hasta los 7 días posteriores al procedimiento de las técnicas de IVE. Finalmente, se hace análisis descriptivo. Resultados: durante el periodo de estudio hubo 1.520 mujeres elegibles de las cuales 46 fueron intervenidas en otras instituciones por lo que quedaron 1.474 candidatas a ingresar al estudio, de estas se excluyeron 30 por presentar infecciones pélvicas o de transmisión sexual, por lo que, finalmente, se analizaron 1.444 mujeres gestantes. Los riesgos para la salud de la mujer fueron la causa legal más frecuente con un 94,3%. El 99% de las mujeres tenían asesoría previa, y el 78,4% aceptó algún método anticonceptivo post-IVE. El 95,6% de las mujeres fueron intervenidas por la técnica de aspiración manual endouterina (AMEU) y al 4,4% se la practicó la técnica de dilatación y curetaje (D&C). En un 17,56% de las pacientes intervenidas con D&C se presentaron complicaciones hasta el séptimo día posoperatorio, no hubo complicaciones en el grupo sometido a AMEU, el 80% de las mujeres asistieron a control el séptimo día post-IVE. Conclusiones: la AMEU es un procedimiento seguro que no generó complicaciones intraoperatorias en el procedimiento, mientras la D&C se acompañó de complicaciones en una de cada seis pacientes. Se requieren estudios prospectivos que evalúen la seguridad y costos de las diferentes alternativas de IVE.

ABSTRACT Objectives: To characterize a cohort of women with voluntary interruption of pregnancy (VIP) and to describe intraoperative complications according to the technique used. Materials and methods: Descriptive study in a historical cohort of women undergoing VIP in two healthcare institutions in Medellín, Colombia, in 2019. Women with pelvic infection and Sexually Transmitted Infections (STIs) were included. Consecutive sampling was used. Sociodemographic, sexual and reproductive health, clinical characteristics of the pregnancy, legal cause of the VIP, characteristics of the care process and complications of the VIP techniques up to postprocedural day 7 were the measured variables. A descriptive analysis was carried out. Results: Overall, 1,520 women were identified as eligible during the study period. Of them, 46 were intervened in other institutions, leaving 1,474 candidates to enter the study. Of them, 30 were excluded because of pelvic or sexually transmitted infections. Ultimately, 1,444 pregnant women were included in the analysis. Risk to the mother's health was the most frequent legal cause in 94.3% of cases. Ninety-nine percent of women received pre-procedural counseling, and 78.4% agreed to use some form of contraception after VIP. Manual vacuum aspiration (MVA) was used in 95.6% of women and dilation and curettage (D&C) in 4.4%. Complications up to postoperative day 7 occurred in 17.56%, and there were no complications in the MVA group; 80% of women attended the follow-up visit on post-VIP day 7. Conclusions: MVA is a safe procedure which was not associated with intraperatory comoplications. D&C was associated to complications in one of each six patients. Prospective studies to assess the safety and cost of the different VIP options are required.